Attovia Therapeutics (NASDAQ:ATTO) Research Coverage Started at Royal Bank Of Canada

Royal Bank Of Canada initiated coverage on shares of Attovia Therapeutics (NASDAQ:ATTO) in a research note issued to investors on Monday morning, Marketbeat reports. The firm issued an outperform rating and a $45.00 target price on the stock.

Other equities research analysts have also issued reports about the stock. Citigroup initiated coverage on shares of Attovia Therapeutics in a research note on Monday. They set a “buy” rating and a $30.00 price target on the stock. Leerink Partners began coverage on shares of Attovia Therapeutics in a research note on Monday. They issued an “outperform” rating and a $52.00 price objective for the company. Finally, Morgan Stanley started coverage on Attovia Therapeutics in a report on Monday. They set an “overweight” rating and a $39.00 price objective on the stock. Five equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $42.20.

Attovia Therapeutics Stock Performance

NASDAQ:ATTO opened at $23.13 on Monday. Attovia Therapeutics has a 12 month low of $16.15 and a 12 month high of $24.32.

Attovia Therapeutics (NASDAQ:ATTO) last issued its earnings results on Wednesday, September 2nd. The company reported ($4.88) earnings per share for the quarter.

Insiders Place Their Bets

In other Attovia Therapeutics news, major shareholder Goldman Sachs Group Inc bought 500,000 shares of the business’s stock in a transaction dated Thursday, August 6th. The shares were acquired at an average cost of $17.00 per share, with a total value of $8,500,000.00. Following the acquisition, the insider directly owned 3,020,632 shares of the company’s stock, valued at $51,350,744. The trade was a 19.84% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Life Sciences Xi L.P. Frazier purchased 588,235 shares of Attovia Therapeutics stock in a transaction that occurred on Thursday, August 6th. The stock was acquired at an average price of $17.00 per share, with a total value of $9,999,995.00. Following the transaction, the insider owned 6,154,213 shares in the company, valued at $104,621,621. The trade was a 10.57% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders acquired 2,740,587 shares of company stock valued at $47,269,979. 0.99% of the stock is owned by insiders.

More Attovia Therapeutics News

Here are the key news stories impacting Attovia Therapeutics this week:

• Positive Sentiment: Positive ATTO-1310 clinical update: Attovia reported preliminary proof of concept for ATTO-1310 in chronic pruritus and high-itch atopic dermatitis. Complete Phase 1b data are expected in the fourth quarter of 2026, providing a near-term catalyst. Attovia Therapeutics second-quarter results and corporate update
• Positive Sentiment: New bullish analyst coverage: LifeSci Capital initiated coverage with an “outperform” recommendation. Citigroup, Leerink Partners and Royal Bank of Canada also began coverage, increasing institutional visibility around the biotech. LifeSci Capital coverage
• Positive Sentiment: Royal Bank of Canada recently upgraded Attovia to “moderate buy,” reinforcing the positive analyst sentiment surrounding the company’s pipeline. Royal Bank of Canada upgrade
• Neutral Sentiment: Attovia’s second-quarter earnings release provides investors with an updated financial and corporate overview, with attention likely focused on development spending and the company’s ability to fund upcoming clinical work. Attovia Therapeutics earnings press release
• Negative Sentiment: Widening quarterly loss: Attovia reported a second-quarter loss of $4.88 per share, while separate coverage characterized the company’s net loss as wider than in the prior-year period. Continued losses could weigh on the stock if investors become concerned about cash needs or execution risk. Attovia Therapeutics Q2 net loss

About Attovia Therapeutics

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.